A citation-based method for searching scientific literature

Salah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, Thorsten O Goetze, Johannes Meiler, Stefan Kasper, Hans-Georg Kopp, Frank Mayer, Georg Martin Haag, Kim Luley, Udo Lindig, Wolff Schmiegel, Michael Pohl, Jan Stoehlmacher, Gunnar Folprecht, Stephan Probst, Nicole Prasnikar, Wolfgang Fischbach, Rolf Mahlberg, Jörg Trojan, Michael Koenigsmann, Uwe M Martens, Peter Thuss-Patience, Matthias Egger, Andreas Block, Volker Heinemann, Gerald Illerhaus, Markus Moehler, Michael Schenk, Frank Kullmann, Dirk M Behringer, Michael Heike, Daniel Pink, Christian Teschendorf, Carmen Löhr, Helga Bernhard, Gunter Schuch, Volker Rethwisch, Ludwig Fischer von Weikersthal, Jörg T Hartmann, Michael Kneba, Severin Daum, Karsten Schulmann, Jörg Weniger, Sebastian Belle, Timo Gaiser, Fuat S Oduncu, Martina Güntner, Wael Hozaeel, Alexander Reichart, Elke Jäger, Thomas Kraus, Stefan Mönig, Wolf O Bechstein, Martin Schuler, Harald Schmalenberg, Ralf D Hofheinz. Lancet 2019
Times Cited: 680







List of co-cited articles
368 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
David Cunningham, William H Allum, Sally P Stenning, Jeremy N Thompson, Cornelis J H Van de Velde, Marianne Nicolson, J Howard Scarffe, Fiona J Lofts, Stephen J Falk, Timothy J Iveson,[...]. N Engl J Med 2006
49

Preoperative chemoradiotherapy for esophageal or junctional cancer.
P van Hagen, M C C M Hulshof, J J B van Lanschot, E W Steyerberg, M I van Berge Henegouwen, B P L Wijnhoven, D J Richel, G A P Nieuwenhuijzen, G A P Hospers, J J Bonenkamp,[...]. N Engl J Med 2012
33

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.
Marc Ychou, Valérie Boige, Jean-Pierre Pignon, Thierry Conroy, Olivier Bouché, Gilles Lebreton, Muriel Ducourtieux, Laurent Bedenne, Jean-Michel Fabre, Bernard Saint-Aubert,[...]. J Clin Oncol 2011
27

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
26

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Joel Shapiro, J Jan B van Lanschot, Maarten C C M Hulshof, Pieter van Hagen, Mark I van Berge Henegouwen, Bas P L Wijnhoven, Hanneke W M van Laarhoven, Grard A P Nieuwenhuijzen, Geke A P Hospers, Johannes J Bonenkamp,[...]. Lancet Oncol 2015
20

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
20

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Ronan J Kelly, Jaffer A Ajani, Jaroslaw Kuzdzal, Thomas Zander, Eric Van Cutsem, Guillaume Piessen, Guillermo Mendez, Josephine Feliciano, Satoru Motoyama, Astrid Lièvre,[...]. N Engl J Med 2021
181
18



Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Yung-Jue Bang, Young-Woo Kim, Han-Kwang Yang, Hyun Cheol Chung, Young-Kyu Park, Kyung Hee Lee, Keun-Wook Lee, Yong Ho Kim, Sang-Ik Noh, Jae Yong Cho,[...]. Lancet 2012
15

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Yelena Y Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli,[...]. Lancet 2021
187
15

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
14

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
E C Smyth, M Verheij, W Allum, D Cunningham, A Cervantes, D Arnold. Ann Oncol 2016
756
14

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
Charles S Fuchs, Toshihiko Doi, Raymond W Jang, Kei Muro, Taroh Satoh, Manuela Machado, Weijing Sun, Shadia I Jalal, Manish A Shah, Jean-Phillipe Metges,[...]. JAMA Oncol 2018
834
12

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Shinichi Sakuramoto, Mitsuru Sasako, Toshiharu Yamaguchi, Taira Kinoshita, Masashi Fujii, Atsushi Nashimoto, Hiroshi Furukawa, Toshifusa Nakajima, Yasuo Ohashi, Hiroshi Imamura,[...]. N Engl J Med 2007
11

Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.
Mitsuru Sasako, Shinichi Sakuramoto, Hitoshi Katai, Taira Kinoshita, Hiroshi Furukawa, Toshiharu Yamaguchi, Atsushi Nashimoto, Masashi Fujii, Toshifusa Nakajima, Yasuo Ohashi. J Clin Oncol 2011
863
11


Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Kohei Shitara, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun-Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee,[...]. N Engl J Med 2020
240
11


Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction.
Michael Stahl, Martin K Walz, Martin Stuschke, Nils Lehmann, Hans-Joachim Meyer, Jorge Riera-Knorrenschild, Peter Langer, Rita Engenhart-Cabillic, Michael Bitzer, Alfred Königsrainer,[...]. J Clin Oncol 2009
622
10


Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
J S Macdonald, S R Smalley, J Benedetti, S A Hundahl, N C Estes, G N Stemmermann, D G Haller, J A Ajani, L L Gunderson, J M Jessup,[...]. N Engl J Med 2001
10

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Annemieke Cats, Edwin P M Jansen, Nicole C T van Grieken, Karolina Sikorska, Pehr Lind, Marianne Nordsmark, Elma Meershoek-Klein Kranenbarg, Henk Boot, Anouk K Trip, H A Maurits Swellengrebel,[...]. Lancet Oncol 2018
231
10

Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Sung Hoon Noh, Sook Ryun Park, Han-Kwang Yang, Hyun Cheol Chung, Ik-Joo Chung, Sang-Woon Kim, Hyung-Ho Kim, Jin-Hyuk Choi, Hoon-Kyo Kim, Wansik Yu,[...]. Lancet Oncol 2014
561
10

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Charles S Fuchs, Jiri Tomasek, Cho Jae Yong, Filip Dumitru, Rodolfo Passalacqua, Chanchal Goswami, Howard Safran, Lucas Vieira Dos Santos, Giuseppe Aprile, David R Ferry,[...]. Lancet 2014
9

Capecitabine and oxaliplatin for advanced esophagogastric cancer.
David Cunningham, Naureen Starling, Sheela Rao, Timothy Iveson, Marianne Nicolson, Fareeda Coxon, Gary Middleton, Francis Daniel, Jacqueline Oates, Andrew Richard Norman. N Engl J Med 2008
8

Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.
Ilfet Songun, Hein Putter, Elma Meershoek-Klein Kranenbarg, Mitsuru Sasako, Cornelis J H van de Velde. Lancet Oncol 2010
8



Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Hansjochen Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, György Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae-You Kim,[...]. Lancet Oncol 2014
8

Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.
Filippo Pietrantonio, Rosalba Miceli, Alessandra Raimondi, Young Woo Kim, Won Ki Kang, Ruth E Langley, Yoon Young Choi, Kyoung-Mee Kim, Matthew Guy Nankivell, Federica Morano,[...]. J Clin Oncol 2019
123
8

Gastric cancer.
Elizabeth C Smyth, Magnus Nilsson, Heike I Grabsch, Nicole Ct van Grieken, Florian Lordick. Lancet 2020
565
7

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
7

Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
Stephen R Smalley, Jacqueline K Benedetti, Daniel G Haller, Scott A Hundahl, Norman C Estes, Jaffer A Ajani, Leonard L Gunderson, Bryan Goldman, James A Martenson, J Milburn Jessup,[...]. J Clin Oncol 2012
525
7

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Peter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, Eric Van Cutsem, Jaffer A Ajani, Hugo Castro, Wasat Mansoor, Hyun Cheol Chung, Gyorgy Bodoky, Kohei Shitara,[...]. Lancet Oncol 2017
227
7

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.
David Cunningham, Sally P Stenning, Elizabeth C Smyth, Alicia F Okines, William H Allum, Sam Rowley, Laura Stevenson, Heike I Grabsch, Derek Alderson, Thomas Crosby,[...]. Lancet Oncol 2017
157
7

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kohei Shitara, Toshihiko Doi, Mikhail Dvorkin, Wasat Mansoor, Hendrik-Tobias Arkenau, Aliaksandr Prokharau, Maria Alsina, Michele Ghidini, Catia Faustino, Vera Gorbunova,[...]. Lancet Oncol 2018
195
7

Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.
Elizabeth C Smyth, Andrew Wotherspoon, Clare Peckitt, David Gonzalez, Sanna Hulkki-Wilson, Zakaria Eltahir, Matteo Fassan, Massimo Rugge, Nicola Valeri, Alicia Okines,[...]. JAMA Oncol 2017
239
7

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Jong-Mu Sun, Lin Shen, Manish A Shah, Peter Enzinger, Antoine Adenis, Toshihiko Doi, Takashi Kojima, Jean-Philippe Metges, Zhigang Li, Sung-Bae Kim,[...]. Lancet 2021
79
8

Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial.
Bo Jan Noordman, Bas P L Wijnhoven, Sjoerd M Lagarde, Jurjen J Boonstra, Peter Paul L O Coene, Jan Willem T Dekker, Michael Doukas, Ate van der Gaast, Joos Heisterkamp, Ewout A Kouwenhoven,[...]. BMC Cancer 2018
97
6

ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).
Jens Hoeppner, Florian Lordick, Thomas Brunner, Torben Glatz, Peter Bronsert, Nadine Röthling, Claudia Schmoor, Dietmar Lorenz, Christian Ell, Ulrich T Hopt,[...]. BMC Cancer 2016
134
6


Global burden of oesophageal and gastric cancer by histology and subsite in 2018.
Melina Arnold, Jacques Ferlay, Mark I van Berge Henegouwen, Isabelle Soerjomataram. Gut 2020
80
7

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
Josep Tabernero, Paulo M Hoff, Lin Shen, Atsushi Ohtsu, Manish A Shah, Karen Cheng, Chunyan Song, Haiyan Wu, Jennifer Eng-Wong, Katherine Kim,[...]. Lancet Oncol 2018
182
6

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
Kohei Shitara, Eric Van Cutsem, Yung-Jue Bang, Charles Fuchs, Lucjan Wyrwicz, Keun-Wook Lee, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee,[...]. JAMA Oncol 2020
188
6

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Kohei Shitara, Mustafa Özgüroğlu, Yung-Jue Bang, Maria Di Bartolomeo, Mario Mandalà, Min-Hee Ryu, Lorenzo Fornaro, Tomasz Olesiński, Christian Caglevic, Hyun C Chung,[...]. Lancet 2018
599
6

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Ken Kato, Byoung Chul Cho, Masanobu Takahashi, Morihito Okada, Chen-Yuan Lin, Keisho Chin, Shigenori Kadowaki, Myung-Ju Ahn, Yasuo Hamamoto, Yuichiro Doki,[...]. Lancet Oncol 2019
342
6

Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.
Derek Alderson, David Cunningham, Matthew Nankivell, Jane M Blazeby, S Michael Griffin, Adrian Crellin, Heike I Grabsch, Rupert Langer, Susan Pritchard, Alicia Okines,[...]. Lancet Oncol 2017
123
6

Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy.
Karen Becker, James D Mueller, Christoph Schulmacher, Katja Ott, Ulrich Fink, Raymonde Busch, Knut Böttcher, J Rüdiger Siewert, Heinz Höfler. Cancer 2003
449
6

Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations.
A M Mandard, F Dalibard, J C Mandard, J Marnay, M Henry-Amar, J F Petiot, A Roussel, J H Jacob, P Segol, G Samama. Cancer 1994
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.